Biogen
BIIB
818 hedge funds and large institutions have $71B invested in Biogen in 2014 Q3 according to their latest regulatory filings, with 91 funds opening new positions, 312 increasing their positions, 278 reducing their positions, and 47 closing their positions.
94% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 47
14% more funds holding in top 10
Funds holding in top 10: 36 → 41 (+5)
12% more repeat investments, than reductions
Existing positions increased: 312 | Existing positions reduced: 278
5% more funds holding
Funds holding: 782 → 818 (+36)
4% more capital invested
Capital invested by funds: $68.4B → $71B (+$2.54B)
39% less call options, than puts
Call options by funds: $754M | Put options by funds: $1.23B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$197M |
| 2 |
Winslow Capital Management
Minneapolis,
Minnesota
|
+$148M |
| 3 |
WBC
Westpac Banking Corp
Sydney,
Australia
|
+$139M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$122M |
| 5 |
Millennium Management
New York
|
+$116M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$904M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$706M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$549M |
| 4 |
Jennison Associates
New York
|
-$156M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$90.4M |
BIIB Hedge Fund Activity: Q3 2014 in Review
818 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q3 2014, worth a combined $71B — up 3.7% from $68.4B a quarter earlier.
Buyers outnumbered sellers: 91 funds opened new BIIB positions and 47 closed out — a net gain of 44 holders — while 312 added to existing stakes and 278 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $197M. The largest seller was Capital Research Global Investors, cutting an estimated $904M.
- 818 institutional investors held Biogen (BIIB) as of Q3 2014, up from 782 in Q2 2014.
- Funds reported $71B of Biogen stock for Q3 2014, up 3.7% quarter-over-quarter.
- 91 funds opened new Biogen positions in Q3 2014 and 47 closed out, a net change of +44 holders.
- The largest Biogen buyer in Q3 2014 was T. Rowe Price Associates, an estimated $197M added.
- The largest Biogen seller in Q3 2014 was Capital Research Global Investors, an estimated $904M sold.
Based on aggregated 13F filings for Q3 2014.